WordNet

a drug that neutralizes or counteracts the effects of another drug
a muscle that relaxes while another contracts; "when bending the elbow the triceps are the antagonist"
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
the 5th letter of the Roman alphabet (同)e

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 上皮成長因子受容体変異を有する進行性非小細胞肺癌に対する初期全身療法 initial systemic therapy for advanced non small cell lung cancer with a mutation in the epidermal growth factor receptor
2. 転移性乳癌の全身治療：生物学的療法 systemic treatment for metastatic breast cancer biologic therapy
3. 上皮成長因子受容体変異またはALK融合癌遺伝子を有さない進行性非小細胞肺癌に対
する初期全身療法 initial systemic therapy for advanced non small cell lung cancer without an epidermal growth factor receptor mutation or the alk fusion oncogene
4. 慢性腎臓病の二次的要因と進行 secondary factors and progression of chronic kidney disease
5. 常染色体優性多発性嚢胞腎の経過および治療 course and treatment of autosomal dominant polycystic kidney disease

Epidermal growth factor receptor transactivation by intracellular prostaglandin E2-activated prostaglandin E2 receptors. Role in retinoic acid receptor-β up-regulation.

Fernández-Martínez AB, Lucio Cazaña FJ.SourceDepartamento de Biología de Sistemas, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain. Electronic address: anab.fernandez@uah.es.
Biochimica et biophysica acta.Biochim Biophys Acta.2013 Sep;1832(9):2029-38. doi: 10.1016/j.bbamcr.2013.04.013. Epub 2013 May 2.
The pharmacological modulation of renoprotective factor vascular endothelial growth factor-A (VEGF-A) in the proximal tubule has therapeutic interest. In human proximal tubular HK-2 cells, treatment with all-trans retinoic acid or prostaglandin E2 (PGE2) triggers the production of VEGF-A. The pathwa
PMID 23644172

Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?

Rossi A, Pasquale R, Esposito C, Normanno N.SourceDivision of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. arossi_it@yahoo.it
Cancer treatment reviews.Cancer Treat Rev.2013 Aug;39(5):489-97. doi: 10.1016/j.ctrv.2012.09.001. Epub 2012 Sep 28.
An ideal target-based agent for the treatment of cancer patients should fulfil a number of requirements, including the availability of biomarkers to select the target population, superiority over existing treatments and specific advantages in terms of pharmacokinetics and/or metabolism. Epidermal gr
PMID 23022519

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.

Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Oyen WJ, van der Graaf WT, van Laarhoven HW.SourceDepartment of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. s.heskamp@nucmed.umcn.nl
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Jul 15;133(2):307-14. doi: 10.1002/ijc.28046. Epub 2013 Feb 15.
Bevacizumab (antivascular endothelial growth factor [anti-VEGF]) and cetuximab (antiepidermal growth factor receptor [anti-EGFR]) are approved antibodies for treatment of cancer. However, in advanced colorectal cancer, the combination fails to improve survival. As the reason for the lack of activity
PMID 23335047